This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bomgaars, L. Articles by Blaney, S.M. Search for Related Content PubMed PubMed Citation Articles by Bomgaars, L. Articles by Blaney, S.M. Social Bookmarking                            What's this?

Phase I Trial of Intrathecal Liposomal Cytarabine in Children With Neoplastic Meningitis

From the Texas Children's Cancer Center/Baylor College of Medicine, Houston; University of Texas Southwestern Medical School, Dallas TX; Children's Hospital and Medical Center, Seattle, WA; Children's Hospital Los Angeles, Los Angeles; Stanford University Medical Center, Stanford, CA

Address reprint requests to Lisa Bomgaars, MD, Texas Children's Cancer Center, 6621 Fannin, MC 3-3320, Houston, TX 77030; e-mail: lbomgaars{at}txccc.org

PURPOSE: We performed a phase I trial of intrathecal (IT) liposomal cytarabine (DepoCyt; Enzon Pharmaceuticals, Piscataway, NJ and SkyePharma Inc, San Diego, CA) to determine the maximum-tolerated dose, the dose-limiting toxicities, and the plasma and CSF pharmacokinetics of IT lipsomal cytarabine in children 3 years of age with advanced meningeal malignancies.

PATIENTS AND METHODS: Eighteen assessable patients received IT liposomal cytarabine through either an indwelling ventricular access device or via lumbar puncture. Liposomal cytarabine was given once every 2 weeks during induction, once every 4 weeks during consolidation, and once every 8 weeks during the maintenance phase of treatment. The initial dose was 25 mg, with subsequent escalations to 35 and 50 mg. CSF pharmacokinetic samples were obtained in a subset of patients.

RESULTS: Arachnoiditis, characterized by fever, headache, nausea, vomiting, and back pain was noted in the first two patients at the 25 mg dose level. Therefore, subsequent patients were treated with dexamethasone, beginning the day of liposomal cytarabine administration and continuing for 5 days. Headache (grade 3) was dose limiting in two of eight patients enrolled at the 50 mg dose level. Eight of the 14 patients assessable for response demonstrated evidence of benefit manifest as prolonged disease stabilization or response.

CONCLUSION: The maximum-tolerated dose and recommended phase II dose of liposomal cytarabine in patients between the ages of 3 and 21 years is 35 mg, administered with dexamethasone (0.15 mg/kg/dose, twice a day for 5 days). A phase II trial of IT liposomal cytarabine in children with CNS leukemia in second or higher relapse is in development.

Supported by DepoTech Corporation/Skye Pharma Inc, San Diego, CA.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. L de Lemos, S. Monfared, T. Denyssevych, L. Hamata, S. Jennings, B. Thiessen, S. Smith, and D. Waterhouse Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration Journal of Oncology Pharmacy Practice, March 1, 2009; 15(1): 45 - 52. [Abstract] [PDF]

				J. Salzburg, B. Burkhardt, M. Zimmermann, O. Wachowski, W. Woessmann, I. Oschlies, W. Klapper, H.-H. Wacker, W.-D. Ludwig, F. Niggli, et al. Prevalence, Clinical Pattern, and Outcome of CNS Involvement in Childhood and Adolescent Non-Hodgkin's Lymphoma Differ by Non-Hodgkin's Lymphoma Subtype: A Berlin-Frankfurt-Munster Group Report J. Clin. Oncol., September 1, 2007; 25(25): 3915 - 3922. [Abstract] [Full Text] [PDF]

				E. Jabbour, S. O'Brien, H. Kantarjian, G. Garcia-Manero, A. Ferrajoli, F. Ravandi, M. Cabanillas, and D. A. Thomas Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia Blood, April 15, 2007; 109(8): 3214 - 3218. [Abstract] [Full Text] [PDF]

				A. Reiter Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma Hematology, January 1, 2007; 2007(1): 285 - 296. [Abstract] [Full Text] [PDF]

				S. Gururangan, W. P. Petros, T. Y. Poussaint, M. L. Hancock, P. C. Phillips, H. S. Friedman, L. Bomgaars, S. M. Blaney, L. E. Kun, and J. M. Boyett Phase I Trial of Intrathecal Spartaject Busulfan in Children with Neoplastic Meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004) Clin. Cancer Res., March 1, 2006; 12(5): 1540 - 1546. [Abstract] [Full Text] [PDF]

				C.-H. Pui and W. E. Evans Treatment of Acute Lymphoblastic Leukemia N. Engl. J. Med., January 12, 2006; 354(2): 166 - 178. [Full Text] [PDF]

				C.-H. Pui Central Nervous System Disease in Acute Lymphoblastic Leukemia: Prophylaxis and Treatment Hematology, January 1, 2006; 2006(1): 142 - 146. [Abstract] [Full Text] [PDF]

				S. Chowdhary and M. Chamberlain Leptomeningeal Metastases: Current Concepts and Management Guidelines J Natl Compr Canc Netw, September 1, 2005; 3(5): 693 - 703. [Abstract] [PDF]